Mechanism-Based Covalent Neuraminidase Inhibitors with Broad-Spectrum Influenza Antiviral Activity

Adding to the Antiviral Arsenal The envelope of influenza virus contains two immunodominant glycoproteins: hemagglutinin and neuraminidase (NA). Existing antivirals like zanamivir (Relenza) and oseltamivir (Tamiflu) target NA; however, the development of drug resistance is a problem. Kim et al. (p. 71, published online 21 February) now report a different class of NA inhibitors. NA catalyzes the removal of sialic acids from the surface of host cells to initiate entry. Discovery of a NA–sialic acid intermediate led to the production of sialic acid analogs that bound covalently to NA and inhibited its enzymatic activity. These compounds showed activity against a wide variety of influenza strains, inhibited viral replication in cell culture, and were able to protect mice against influenza infection. Protection of mice was equivalent to protection seen from zanamivir. Moreover, the compounds showed activity against drug-resistant strains in vitro. These compounds represent a potentially useful addition to the arsenal of antivirals used to treat influenza infection. Looking deeply into the mechanism of enzyme inhibition provides a clue for the development of new drugs to fight flu. Influenza antiviral agents play important roles in modulating disease severity and in controlling pandemics while vaccines are prepared, but the development of resistance to agents like the commonly used neuraminidase inhibitor oseltamivir may limit their future utility. We report here on a new class of specific, mechanism-based anti-influenza drugs that function through the formation of a stabilized covalent intermediate in the influenza neuraminidase enzyme, and we confirm this mode of action with structural and mechanistic studies. These compounds function in cell-based assays and in animal models, with efficacies comparable to that of the neuraminidase inhibitor zanamivir and with broad-spectrum activity against drug-resistant strains in vitro. The similarity of their structure to that of the natural substrate and their mechanism-based design make these attractive antiviral candidates.

[1]  P. Collins,et al.  H1N1 2009 Pandemic Influenza Virus: Resistance of the I223R Neuraminidase Mutant Explained by Kinetic and Structural Analysis , 2012, PLoS pathogens.

[2]  V. Streltsov,et al.  In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir. , 2012, The Journal of antimicrobial chemotherapy.

[3]  P. Andrew Karplus,et al.  Linking Crystallographic Model and Data Quality , 2012, Science.

[4]  J. McKimm-Breschkin,et al.  Real Time Enzyme Inhibition Assays Provide Insights into Differences in Binding of Neuraminidase Inhibitors to Wild Type and Mutant Influenza Viruses , 2011, PloS one.

[5]  Samir N. Patel,et al.  Multidrug-Resistant Pandemic (H1N1) 2009 Infection in Immunocompetent Child , 2011, Emerging infectious diseases.

[6]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[7]  Ha T. Nguyen,et al.  Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  C. Boucher,et al.  Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. , 2010, The New England journal of medicine.

[9]  Thomas S. Peat,et al.  Structural and Functional Basis of Resistance to Neuraminidase Inhibitors of Influenza B Viruses† , 2010, Journal of medicinal chemistry.

[10]  Concepción C. González,et al.  Synthesis of guanidines from azides: a general and straightforward methodology in carbohydrate chemistry. , 2010, The Journal of organic chemistry.

[11]  Nobuhiro Suzuki,et al.  Complexity in influenza virus targeted drug design: interaction with human sialidases. , 2010, Journal of medicinal chemistry.

[12]  Martijn Gough.  Climate change , 2009, Canadian Medical Association Journal.

[13]  C. Macken,et al.  Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996–2007 , 2009, Antiviral therapy.

[14]  Alan J. Hay,et al.  Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants , 2008, Nature.

[15]  Andrew G. Watts,et al.  The Structure of Clostridium perfringens NanI Sialidase and Its Catalytic Intermediates* , 2008, Journal of Biological Chemistry.

[16]  Mark von Itzstein,et al.  The war against influenza: discovery and development of sialidase inhibitors , 2007, Nature Reviews Drug Discovery.

[17]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[18]  Catherine Macken,et al.  Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use , 2006, Antimicrobial Agents and Chemotherapy.

[19]  I. Barr,et al.  Neuraminidase Inhibitor-Resistant and -Sensitive Influenza B Viruses Isolated from an Untreated Human Patient , 2006, Antimicrobial Agents and Chemotherapy.

[20]  Andrew G. Watts,et al.  Structural and Kinetic Analysis of Two Covalent Sialosyl-Enzyme Intermediates on Trypanosoma rangeli Sialidase* , 2006, Journal of Biological Chemistry.

[21]  Andrew G. Watts,et al.  The synthesis of some mechanistic probes for sialic acid processing enzymes and the labeling of a sialidase from Trypanosoma rangeli , 2004 .

[22]  Yoshihiro Kawaoka,et al.  oseltamivir: descriptive study , 2022 .

[23]  Andrew G. Watts,et al.  Trypanosoma cruzi trans-sialidase operates through a covalent sialyl-enzyme intermediate: tyrosine is the catalytic nucleophile. , 2003, Journal of the American Chemical Society.

[24]  Peter Kuhn,et al.  Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines. , 2002, Journal of synchrotron radiation.

[25]  S. Baird,et al.  Pattern of mutation in the genome of influenza A virus on adaptation to increased virulence in the mouse lung: Identification of functional themes , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D E McRee,et al.  XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. , 1999, Journal of structural biology.

[27]  Paul W Smith,et al.  Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. , 1998, Structure.

[28]  Konrad Feichtinger,et al.  Diprotected Triflylguanidines: A New Class of Guanidinylation Reagents , 1998 .

[29]  P. Colman,et al.  Mutations in a Conserved Residue in the Influenza Virus Neuraminidase Active Site Decreases Sensitivity to Neu5Ac2en-Derived Inhibitors , 1998, Journal of Virology.

[30]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[31]  R. Webster,et al.  Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en , 1997, Journal of virology.

[32]  P. Colman,et al.  Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. , 1995, Virology.

[33]  P. Colman,et al.  Three‐dimensional structure of the complex of 4‐guanidino‐Neu5Ac2en and influenza virus neuraminidase , 1995, Protein science : a publication of the Protein Society.

[34]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[35]  M. Itzstein,et al.  A convenient method for the introduction of nitrogen and sulfur at C-4 on a sialic acid analogue , 1993 .

[36]  A. Brunger.  Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. , 1992 .

[37]  G. Air,et al.  Influenza virus neuraminidase with hemagglutinin activity. , 1984, Virology.

[38]  C. Wilkinson.  Status of coral reefs of the world , 2000 .

[39]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[40]  M. A. Wright,et al.  Synthesis of the potent influenza neuraminidase inhibitor 4-guanidino Neu5Ac2en. X-Ray molecular structure of 5-acetamido-4-amino-2,6-anhydro-3,4,5-trideoxy-D-erythro-L-gluco-nononic acid , 1995 .